Multiphenotypic acute leukemias: clinicopathologic correlations and response to therapy.
Multiphenotypic acute leukemias (MAL), defined by the coexpression on most blast cells of antigens classically attributed to different lineages, remain a rare event. We isolated a series of 26 such cases from a cohort of 1565 leukemic patients whose cells were immunophenotyped at diagnosis. Markers of B and myeloid lineage (BM) were associated in 16 cases (62%), 3 coexpressed B and T markers (BT), and T-cell and myeloid antigens (TM) were found in 7 (27%). A tumoral syndrome was observed in 69% of the patients, without significant differences between the immunophenotypic subgroups. Median event free survivals in the three immunophenotypic subgroups as defined were respectively 24 months for BM-MAL, 4 months for TM-MAL and 7 months for BT-MAL respectively. The poorer prognosis of TM-MAL was significantly different from that of BM-MAL (p < 0.001). This concurred with the poorer prognosis associated with CD7 expression or absence or CD10, both characteristic features of TM-MAL.
Philip
P J
PJ
"Unité de Biologie Cellulaire et Tissulaire", Hôpital Pasteur, Nice, France.
Monpoux
F
F
Sudaka
I
I
Baudouin
F
F
Bayle
J
J
Bene
M C
MC
Faure
G C
GC
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D015996:Survival Rate
D015703:Antigens, CD